Fulgent Genetics, Inc. (NasdaqGM: FLGT)
Health Care · Health Care Providers & Services · US
$21.74
+4.42% today · -3.4% 1Y
Fulgent Genetics, Inc. (NasdaqGM: FLGT) operates in the Health Care Providers & Services industry within the Health Care sector. The company is valued at $598.18M and employs 1,315 people.
Over the last twelve months the share price has lost 3.4%, trading between 13.46 and 31.04.
Tweenvest scores Fulgent Genetics, Inc. across four factors: quality 62/100, value 74/100, growth 52/100. Its strongest factor is value.
FLGT price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $598.18M
- Revenue (TTM)
- $323.93M
- P/E
- —
- EPS
- -2.81
- Dividend yield
- —
- Beta (5Y)
- 0.93
- 52-week high
- $31.04
- 52-week low
- $13.46
- Avg volume (3M)
- —
- Shares outstanding
- 27.52M
- Employees
- 1,315
- Next earnings
- —
About Fulgent Genetics, Inc.
Fulgent Genetics, Inc., together with its affiliated companies, offers a comprehensive suite of COVID-19, molecular diagnostic, and genetic testing services to healthcare providers and individuals globally. Their diverse array of genetic tests covers a wide range of applications, including extensive oncology panels and solid tumor molecular profiling for cancer identification, Beacon carrier screening for inherited conditions, and specialized rapid whole genome testing for critically ill infants in NICU and PICU units. Other offerings include a newborn genetic analysis panel, a front-line test to sequence ataxia-related variants, and patient-initiated genetic testing via Picture Genetics. They also provide comprehensive whole exome, clinical exome, whole genome, mutation, and repeat expansion testing, alongside research service tests. For COVID-19, the company delivers next-generation sequencing, reverse transcription polymerase chain reaction (RT-PCR), and antigen-based diagnostic solutions for SARS-CoV-2. Beyond genetic and COVID-19 diagnostics, Fulgent Genetics performs advanced laboratory analyses such as flow cytometry for cell analysis and malignancy monitoring, fluorescence in-situ hybridization (FISH) for specific DNA sequence detection, immunohistochemistry (IHC) to visualize cellular antigens, and cytogenetics for assessing chromosomal anomalies, in addition to molecular testing for both hematopoietic and solid tumors. Their clientele is broad, including insurance companies, hospitals, medical institutions, fellow laboratories, government agencies, payors, municipal bodies, major corporations, and direct patients. The company has formed a strategic partnership with Helio Health, Inc. to commercialize blood-based early cancer detection tests. Founded in 2011 and headquartered in Temple City, California, the company was previously known as Fulgent Diagnostics, Inc. before adopting its current name in August 2016.
- ISIN
- US3596641098
- Founded
- 2011
- Listed since
- Sep 29, 2016
- Exchange
- Nasdaq Global Market
- Currency
- USD
Other Health Care Providers & Services companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Mediterranean Towers Ltd.TASE: MDTR | $616.01M | ₪12.41 | -5.70% |
| Ramkhamhaeng Hospital Public Company LimitedSET: RAM | $615.15M | ฿17.20 | -0.58% |
| Al-Maidan Clinic for Oral Health Services Company K.S.C.P.KWSE: MIDAN | $614.66M | KD0.94 | +5.71% |
| GKHT Medical Technology Co., Ltd.SZSE: 301370 | $613.50M | CN¥8.80 | +0.69% |
| PT Famon Awal Bros Sedaya TbkIDX: PRAY | $592.89M | Rp760.00 | +1.33% |
| Shenzhen Neptunus Bioengineering Co., Ltd.SZSE: 000078 | $573.51M | CN¥1.46 | -2.01% |
| Chabiotech Co.,Ltd.KOSDAQ: A085660 | $564.22M | ₩8,200.00 | -3.07% |
| Integral Diagnostics LimitedASX: IDX | $558.86M | AU$2.15 | +0.94% |
Figures last refreshed Oct 11, 2026.